SUPERNUS PHARMACEUTICALS, INC. (SUPN) Net margin 2016–2025
SUPERNUS PHARMACEUTICALS, INC. (SUPN) net profit margin by fiscal year — reported net income divided by reported revenue.
-5.4%FY2025 · since FY2016: 42.4% → -5.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -5.4% | -16.5 pp |
| FY2024 | 11.2% | +10.9 pp |
| FY2023 | 0.2% | -8.9 pp |
| FY2022 | 9.1% | -0.1 pp |
| FY2021 | 9.2% | -15.2 pp |
| FY2020 | 24.4% | -4.4 pp |
| FY2019 | 28.8% | +1.6 pp |
| FY2018 | 27.1% | +8.2 pp |
| FY2017 | 19.0% | -23.5 pp |
| FY2016 | 42.4% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More SUPN financial trends
SUPN RevenueSUPN Net incomeSUPN Gross profitSUPN Gross marginSUPN Operating incomeSUPN Operating marginSUPN Operating cash flowSUPN Free cash flowSUPN Capital expendituresSUPN Return on equitySUPN Stock buybacksSUPN Dividends paidSUPN Total assetsSUPN Total liabilitiesSUPN Shareholders’ equitySUPN overview →